Are BPC-157 and TB-500 the same kind of molecule?

No. BPC-157 is a synthetic 15-residue pentadecapeptide, while TB-500 as listed here is full-length thymosin beta-4, a 43-residue member of the beta-thymosin family characterised as a G-actin-sequestering peptide.

What does the BPC-157 literature mostly report on?

Most of the indexed record concerns the relation of the pentadecapeptide to the nitric-oxide system and to blood-vessel and collateral-pathway responses in laboratory models, with a further overview covering central-nervous-system preparations.

What does the thymosin beta-4 literature mostly report on?

The thymosin beta-4 record concentrates on its binding of monomeric actin, its interactions with other proteins and its posttranslational modifications, surveyed largely in overviews of the beta-thymosin family.

Does a shared research area mean findings transfer between them?

No. Where both appear in the same field, such as vascular or tissue preparations, they are examined through different molecular routes — the nitric-oxide system for the pentadecapeptide, actin binding and ROCK1 expression for thymosin beta-4 — so a finding for one says nothing about the other.

Research comparison

BPC-157 vs TB-500: what the research literature compares

Updated 5 November 2026Ouralus research desk

Short answer

BPC-157 and TB-500 are unrelated molecules: BPC-157 is a synthetic 15-residue peptide from a gastric-protein literature, while TB-500 is thymosin beta-4, a 43-residue actin-binding peptide. Their literatures measure different things, so this page sets them side by side rather than ranking them.23755725 12852258

This page does not say which is preferable for any purpose, and nothing on this site does.

Compound identifiers, side by side

Property	BPC-157	TB-500
What it is	Synthetic 15–amino-acid peptide (pentadecapeptide)	Thymosin beta-4 (TB4), full-length 43-residue peptide
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val	Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH
CAS	137525-51-0	77591-33-4
Molecular formula	C62H98N16O22	C212H350N56O78S
Molar mass	1419.5 g/mol	4963 g/mol
Research areas in the literature	Angiogenesis, Cytoprotection, Extracellular matrix	Extracellular matrix

Shared research areas: Extracellular matrix. A shared area means the two are examined in the same field of study — not that they are examined through the same mechanism, and not that findings for one transfer to the other.

What each literature examines

The characterization below reflects published research literature only. It describes what that literature examines; it is not a statement about use in people. Both compounds are investigational research material and neither is an approved product.

BPC-157

The indexed BPC-157 literature reports endpoints in the nitric-oxide system, in blood-vessel and collateral-pathway responses, and in central-nervous-system preparations, and comes mostly from a single research group.23755725 23782145 34380875 36200148

Study material

Laboratory models summarised in narrative overviews and an editorial; the indexed record is research literature only, not product studies.23755725 23782145 34380875 36200148

Full BPC-157 reference →

TB-500

Published TB-500 work sits inside the beta-thymosin literature, where the reported endpoints are G-actin binding, posttranslational modification and the structural biology of the thymosin beta-4 family.12852258 17468232 17495248 20536447

Study material

Cell preparations, including hepatic stellate cells, and cardiac-remodelling models, with overviews of the beta-thymosin family making up a large share of the record.26006229 27450733 27450736 40362372

Full TB-500 reference →

Purity, and how to check both yourself

Purity here is a measurement, not a position. The lot currently shipping of each was analysed by an independent laboratory for purity and net content. We do not test our own material. Both certificates state an assayed purity figure.

Measurement	BPC-157	TB-500
Assayed purity, latest report	99.497%	99.402%
Testing laboratory	Janoshik	Janoshik
Lot	Blue Transparent Cap / Silver Crimp	White
Verify key	RMAIPH836PXJ	PDXV8UJEL1G4

Enter either verify key at janoshik.com/verify and the laboratory returns the report it issued for that batch. You are confirming the result with them, not with us. Full certificates: BPC-157 · TB-500

We report assayed purity and net content only. We do not run heavy-metal, microbial, endotoxin, or sterility analysis, and we do not claim it anywhere on this site.

Frequently asked questions

Are BPC-157 and TB-500 the same kind of molecule?: No. BPC-157 is a synthetic 15-residue pentadecapeptide, while TB-500 as listed here is full-length thymosin beta-4, a 43-residue member of the beta-thymosin family characterised as a G-actin-sequestering peptide.23755725 17468232
What does the BPC-157 literature mostly report on?: Most of the indexed record concerns the relation of the pentadecapeptide to the nitric-oxide system and to blood-vessel and collateral-pathway responses in laboratory models, with a further overview covering central-nervous-system preparations.23755725 23782145 36200148 34380875
What does the thymosin beta-4 literature mostly report on?: The thymosin beta-4 record concentrates on its binding of monomeric actin, its interactions with other proteins and its posttranslational modifications, surveyed largely in overviews of the beta-thymosin family.12852258 20536447 17495248
Does a shared research area mean findings transfer between them?: No. Where both appear in the same field, such as vascular or tissue preparations, they are examined through different molecular routes — the nitric-oxide system for the pentadecapeptide, actin binding and ROCK1 expression for thymosin beta-4 — so a finding for one says nothing about the other.23755725 12852258 40362372

Cited literature

Stable gastric pentadecapeptide BPC 157-NO-system relationSikiric P, et al. · Current Pharmaceutical Design · 2014PMID 23755725 ↗
Thymosin beta 4 interactionsBubb MR · Vitamins and Hormones · 2003PMID 12852258 ↗
BPC 157 and blood vesselsSeiwerth S, et al. · Current Pharmaceutical Design · 2014PMID 23782145 ↗
Pentadecapeptide BPC 157 and the central nervous systemVukojevic J, et al. · Neural Regeneration Research · 2022PMID 34380875 ↗
Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral PathwaysSikiric P, et al. · Current Medicinal Chemistry · 2023PMID 36200148 ↗
beta-ThymosinsHannappel E · Annals of the New York Academy of Sciences · 2007PMID 17468232 ↗
The beta-thymosin enigmaSun HQ, et al. · Annals of the New York Academy of Sciences · 2007PMID 17495248 ↗
Thymosin beta4 and its posttranslational modificationsHannappel E · Annals of the New York Academy of Sciences · 2010PMID 20536447 ↗
Potential role of thymosin Beta 4 in liver fibrosisKim J, et al. · International Journal of Molecular Sciences · 2015PMID 26006229 ↗
Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate CellsKim J, et al. · Vitamins and Hormones · 2016PMID 27450733 ↗
Cardioprotection by Thymosin Beta 4Pipes GT, et al. · Vitamins and Hormones · 2016PMID 27450736 ↗
Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult MammalsMaar K, et al. · International Journal of Molecular Sciences · 2025PMID 40362372 ↗

Research-literature characterization, provided for research context only. For laboratory research use only. Not for human consumption.